doi:10.16139/j.1007-9610.2018.05.021

[1] De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer[J]. Mol Oncol,2016,10(3):464-474.
[2] 陈小松, 沈坤炜. 乳腺癌“液体活检”: 血清标志物与循环肿瘤细胞的检测[J]. 分子诊断与治疗杂志,2012,4(6):410-414.
[3] Mandel P, Metais P.Les acides nuleiques du plasma sanguin chez l’homme[J]. CRSeances Soc Biol Fil,1948, 142:241-243
[4] Leon SA, Shapiro B, Sklaroff DM, et al.Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res,1977,37(3):646-650.
[5] Stroun M, Anker P, Maurice P, et al.Neoplastic characteristcs of the DNA found in the plasma of cancer patients[J]. Oncology,1989,46(5):318-322.
[6] Thakur BK, Zhang H, Becker A, et al.Double-stranded DNA in exosomes: a novel biomarker in cancer detection[J]. Cell Res,2014,24(6):766-769.
[7] Siravegna G, Marsoni S, Siena S, et al.Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
[8] 叶青, 江泽飞. 循环肿瘤DNA检测在乳腺癌诊断中的临床应用[J]. 中国癌症杂志,2016,26(11):947-951.
[9] Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al.Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors[J]. Clin Chem,2015,61(1):297-304.
[10] Watanabe M, Kawaguchi T, Isa S, et al.Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR[J]. Clin Cancer Res,2015,21(15):3552-3560.
[11] Zhu G, Ye X, Dong Z, et al.Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer[J]. J Mol Diagn,2015, 17(3):265-272.
[12] Sacher AG, Paweletz C, Dahlberg SE, et al.Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer[J]. JAMA Oncol,2016,2(8):1014-1022.
[13] Pekin D, Skhiri Y, Baret JC, et al.Quantitative and sensitive detection of rare mutations using droplet-based microfluidics[J]. Lab Chip,2011,11(13):2156-2166.
[14] Oshiro C, Kagara N, Naoi Y, et al.PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients[J]. Breast Cancer Res Treat,2015, 150(2):299-307.
[15] Leary RJ, Kinde I, Diehl F, et al. Development of perso-nalized tumor biomarkers using massively parallel sequencing[J]. Sci Transl Med,2010,2(20):20ra14.
[16] Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J]. Sci Transl Med,2012, 4(162):162ra154.
[17] Wang TL, Maierhofer C, Speicher MR, et al.Digital ka-ryotyping[J]. Proc Natl Acad Sci U S A,2002,99(25):16156-16161.
[18] Paweletz CP, Sacher AG, Raymond CK, et al.Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients[J]. Clin Cancer Res,2016,22(4):915-922.
[19] Shaw JA, Page K, Blighe K, et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy[J]. Genome Res,2012,22(2):220-231.
[20] Murtaza M, Dawson SJ, Pogrebniak K, et al.Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.
[21] Murtaza M, Dawson SJ, Tsui DW, et al.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA[J]. Nature,2013,497(7447):108-112.
[22] Guo S, Diep D, Plongthongkum N, et al.Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA[J]. Nat Genet,2017,49(4):635-642.
[23] Xu RH, Wei W, Krawczyk M, et al.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater,2017,16(11):1155-1161.
[24] Umetani N, Giuliano AE, Hiramatsu SH, et al.Prediction of breast tumor progression by integrity of free circulating DNA in serum[J]. J Clin Oncol,2006,24(26):4270-4276.
[25] Stoetzer OJ, Fersching DM, Salat C, et al.Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin[J]. Cancer Lett,2013,336(1):140-148.
[26] Beaver JA, Jelovac D, Balukrishna S, et al.Detection of cancer DNA in plasma of patients with early-stage breast cancer[J]. Clin Cancer Res,2014,20(10):2643-2650.
[27] Page K, Guttery DS, Fernandez-Garcia D, et al.Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer[J]. Clin Chem,2017,63(2):532-541.
[28] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med,2014,6(224):224ra24.
[29] Madhavan D, Wallwiener M, Bents K, et al.Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat,2014,146(1):163-174.
[30] Olsson E, Winter C, George A, et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med,2015,7(8):1034-1047.
[31] Dawson SJ, Tsui DW, Murtaza M, et al.Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med,2013,368(13):1199-1209.
[32] Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer[J]. Sci Transl Med,2015,7(302):302ra133.
[33] Takahashi H, Kagara N, Tanei T, et al. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients[J]. Clin Breast Cancer,2017,17(1):61-69.e3.
[34] Riva F, Bidard FC, Houy A, et al.Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer[J]. Clin Chem,2017,63(3):691-699.
[35] Guttery DS, Page K, Hills A, et al.Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer[J]. Clin Chem,2015,61(7):974-982.
[36] Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med,2015,7(313):313ra182.
[37] Gevensleben H, Garcia-Murillas I, Graeser MK, et al.Noninvasive detection of HER2 amplification with plasma DNA digital PCR[J]. Clin Cancer Res,2013,19(12):3276-3284.
[38] Bechmann T, Andersen RF, Pallisgaard N, et al.Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer[J]. J Cancer Res Clin Oncol,2013,139(6):995-1003.
[39] Appierto V, Di Cosimo S, Reduzzi C, et al.How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case[J]. Semin Cancer Biol,2017,44:106-116.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[2]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[4]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[5]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[9]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[10]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[11]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[12]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[13]	LIU Miao, SHEN Yan, FU Xiaohong, HU Jiaojiao, CHEN Qingqing, YING Tao. A comparative study on breast cancer between smaller and larger diameters using conventional ultrasound and contrast-enhanced ultrasound [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 229-233.
[14]	CHEN Yuanyuan, YE Xin, TANG Yongzhe, WANG Jie, HE Qi. Prognosis of invasive micropapillary carcinoma versus invasive ductal carcinoma of the breast: a comparative analysis after propensity score matching [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 353-360.
[15]	CHEN Xiaosong, LI Shuai, WU Jiayi, HUANG Ou, CHAI Weimin, YAO Jiejie, ZHU Ying, XU Chen, CHEN Jiayi, QU Qing, FEI Xiaochun, DING Xiaoyi, LIN Lin, ZHANG Nan, FANG Qiong, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei. Diagnosis, treatment and survival of breast cancer patients in single large hospital: a 10-year analysis [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 149-158.